The majority of OC cases are sporadic, but it is estimated that in 17%, germline mutations in BRCA1 or BRCA2 genes can be identified. BRCA mutated OC has distinct clinical characteristics, increased sensibility to platinum and non-platinum agents, and to DNA damage repair (DDR) targeting agents like PARP inhibitors., which as maintenance therapy after platinum-sensitive relapse, have demonstrated the greatest benefit in this BRCA mutated population. Additionally, somatic BRCA mutations could be identified in patients not harboring germline mutations. The prevalence of germline BRCA mutations (gBRCAm) and somatic mutations (sBRCAm) has been well characterized in different populations, LA population is a paradigm of poly-ethnicity, with a mixture of native, Spanish, Italian, Portuguese and Jewish ancestries, where prevalence of germline, but especially somatic BRCA mutations in OC, has not been studied. Furthermore, somatic testing as first step may be a new option in BRCA testing algorithm that could avoid the necessity for double testing (gBRCA, then sBRCA testing) ,in case of gBRCAm negative result.
Somatic tissue testing
Archived 10-µm sections tumor blocks from the diagnostic biopsy sample of patients will be requested from the local pathology lab from all eligible patients who sign the ICF. Samples will be processed centrally for sBRCAm testing (Myriad Tumor BRACAnalysis). Genotypes of mutated samples tested will be compared to a list of known deleterious mutations. Testing for sBRCA mutations will be done at Myriad Genetics Laboratories Germline BRCA testing A blood sample will be collected from all eligible patients who were positive for sBRCA mutations and sent to Myriad central laboratory for testing the point mutation somatically identified to establish the germline vs somatic origin of the mutation. gBRCA mutated patients genotype will be compared to a list of known deleterious mutations 
